LHNYSEServices-Medical LaboratoriesFiscal year ends December 31
LABCORP HOLDINGS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$318.83+0.88 (+0.28%)
Close on Oct 19, 2026
- Market cap
- $26.14B
- P/E (TTM)
- 26.4
- Dividend yield
- 0.90%
LABCORP HOLDINGS INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $2.90B | $2.76B | $2.73B | $2.77B | $2.75B | $2.63B | $2.59B | $2.55B | $2.52B | $2.48B | $2.35B | $2.34B | 77.7% | +5.5% |
| Biopharma Laboratory Services | $836.20M | $780.60M | $793.00M | $799.10M | $784.80M | $721.30M | $767.00M | $737.70M | $707.00M | $710.90M | – | – | 22.4% | +6.5% |
| Drug Development | – | – | – | – | – | – | – | $737.70M | $707.00M | $710.90M | $694.80M | $719.10M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $522.60M | $458.70M | $419.20M | $450.40M | $482.80M | $427.50M | $359.50M | $387.40M | $441.50M | $417.90M | $353.80M | $386.30M | +8.2% |
| Biopharma Laboratory Services | $142.20M | $120.70M | $136.10M | $132.20M | $123.30M | $106.90M | $130.70M | $120.90M | $107.40M | $99.90M | – | – | +15.3% |
| Corporate Segment [Member] | -$130.00M | -$116.60M | -$100.70M | -$109.90M | -$139.20M | -$132.40M | -$189.10M | -$172.50M | -$180.30M | -$128.90M | -$174.40M | -$169.60M | -6.6% |
| Drug Development | – | – | – | – | – | – | – | $120.90M | $107.40M | $99.90M | $109.10M | $109.00M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Labcorp's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.